Financial Ratios Hangzhou Tigermed Consulting Co., Ltd
Equities
300347
CNE100001KV8
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 56.06 CNY | -1.44% |
|
-8.50% | -1.13% |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 4.06 | 3.88 | 4.3 | 3.7 | 2.16 | |||||
Return on Total Capital | 4.44 | 4.22 | 4.69 | 3.97 | 2.31 | |||||
Return On Equity % | 17.36 | 17.64 | 10.5 | 9.12 | 1.85 | |||||
Return on Common Equity | 17.2 | 16.79 | 10.64 | 9.97 | 1.94 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 47.43 | 43.55 | 39.64 | 38.53 | 33.99 | |||||
SG&A Margin | 15.26 | 12.98 | 11.01 | 11.34 | 14.3 | |||||
EBITDA Margin % | 30.03 | 27.97 | 27.11 | 25.4 | 18.4 | |||||
EBITA Margin % | 28.36 | 26.55 | 25.78 | 23.9 | 16.63 | |||||
EBIT Margin % | 27.52 | 25.77 | 24.87 | 22.89 | 15.29 | |||||
Income From Continuing Operations Margin % | 63.56 | 65.06 | 32.06 | 29.12 | 6.78 | |||||
Net Income Margin % | 54.81 | 55.13 | 28.32 | 27.42 | 6.14 | |||||
Net Avail. For Common Margin % | 54.81 | 55.13 | 28.32 | 27.42 | 6.14 | |||||
Normalized Net Income Margin | 12.25 | 12.53 | 14.1 | 16.4 | 10.11 | |||||
Levered Free Cash Flow Margin | 14.86 | 13.84 | -1.52 | 4.28 | 3.71 | |||||
Unlevered Free Cash Flow Margin | 15.85 | 14.13 | -0.79 | 5.3 | 5.05 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.24 | 0.24 | 0.28 | 0.26 | 0.23 | |||||
Fixed Assets Turnover | 5.76 | 5.77 | 5.79 | 5.28 | 4.18 | |||||
Receivables Turnover (Average Receivables) | 2.56 | 3.03 | 2.73 | 2.19 | 1.73 | |||||
Inventory Turnover (Average Inventory) | 566.25 | 544.16 | 302.27 | 199.06 | 157.49 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 10.22 | 4.5 | 2.98 | 2.74 | 1.72 | |||||
Quick Ratio | 10.17 | 4.46 | 2.95 | 2.72 | 1.68 | |||||
Operating Cash Flow to Current Liabilities | 0.88 | 0.59 | 0.36 | 0.28 | 0.3 | |||||
Days Sales Outstanding (Average Receivables) | 143.13 | 120.39 | 133.79 | 166.66 | 211.88 | |||||
Days Outstanding Inventory (Average Inventory) | 0.65 | 0.67 | 1.21 | 1.83 | 2.32 | |||||
Average Days Payable Outstanding | 19.21 | 15.44 | 13 | 16.37 | 21.23 | |||||
Cash Conversion Cycle (Average Days) | 124.57 | 105.61 | 121.99 | 152.12 | 192.98 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 1.86 | 4.73 | 11.99 | 13.69 | 11.77 | |||||
Total Debt / Total Capital | 1.82 | 4.51 | 10.71 | 12.04 | 10.53 | |||||
LT Debt/Equity | 1.56 | 1.97 | 3.23 | 3.51 | 3 | |||||
Long-Term Debt / Total Capital | 1.53 | 1.89 | 2.89 | 3.08 | 2.69 | |||||
Total Liabilities / Total Assets | 8.45 | 13.21 | 17.36 | 17.61 | 16.07 | |||||
EBIT / Interest Expense | 17.3 | 53.94 | 21.19 | 14.1 | 7.15 | |||||
EBITDA / Interest Expense | 20.15 | 61.53 | 24.37 | 16.65 | 9.44 | |||||
(EBITDA - Capex) / Interest Expense | 17.07 | 46.73 | 18.98 | 14.03 | 6.92 | |||||
Total Debt / EBITDA | 0.32 | 0.64 | 1.34 | 1.68 | 2.12 | |||||
Net Debt / EBITDA | -9.59 | -4.96 | -2.55 | -2.08 | 0.52 | |||||
Total Debt / (EBITDA - Capex) | 0.38 | 0.84 | 1.72 | 1.99 | 2.9 | |||||
Net Debt / (EBITDA - Capex) | -11.33 | -6.53 | -3.27 | -2.47 | 0.7 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 13.88 | 63.32 | 35.91 | 4.21 | -10.58 | |||||
Gross Profit, 1 Yr. Growth % | 16.22 | 49.95 | 23.69 | 1.31 | -21.13 | |||||
EBITDA, 1 Yr. Growth % | 26.72 | 52.14 | 31.72 | -2.39 | -35.23 | |||||
EBITA, 1 Yr. Growth % | 25.92 | 52.88 | 32.01 | -3.43 | -37.76 | |||||
EBIT, 1 Yr. Growth % | 23.2 | 52.93 | 31.16 | -4.1 | -40.28 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 108.03 | 67.16 | -33.02 | -5.36 | -79.17 | |||||
Net Income, 1 Yr. Growth % | 107.9 | 64.26 | -30.19 | 0.91 | -79.99 | |||||
Normalized Net Income, 1 Yr. Growth % | -7.28 | 67.1 | 52.86 | 21.21 | -44.87 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 93.81 | 50.68 | -29.7 | 0.86 | -79.94 | |||||
Accounts Receivable, 1 Yr. Growth % | 13.45 | 59.16 | 44.23 | 19.6 | 6.76 | |||||
Inventory, 1 Yr. Growth % | 291.61 | 29.1 | 264.3 | 5.37 | 36.58 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 60.32 | 64.56 | 18.04 | 11.05 | 14.51 | |||||
Total Assets, 1 Yr. Growth % | 158.95 | 21.71 | 15.61 | 8.14 | -3.4 | |||||
Tangible Book Value, 1 Yr. Growth % | 389.11 | 10.75 | 4.14 | 6.75 | -4.39 | |||||
Common Equity, 1 Yr. Growth % | 281.46 | 12.44 | 8.05 | 7.37 | -1.69 | |||||
Cash From Operations, 1 Yr. Growth % | 89.3 | 42.57 | -4.66 | -15.25 | -4.64 | |||||
Capital Expenditures, 1 Yr. Growth % | 52.07 | 135.54 | 21.7 | -30.06 | 13.64 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 31.35 | 54.96 | -115.15 | -373.59 | -22.49 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 30.98 | 48.2 | -107.69 | -715.25 | -14.77 | |||||
Dividend Per Share, 1 Yr. Growth % | 7.91 | 66.67 | 10 | 3.27 | -47.18 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 17.79 | 36.37 | 48.98 | 19.01 | -3.46 | |||||
Gross Profit, 2 Yr. CAGR % | 23.57 | 32.01 | 36.19 | 11.94 | -10.61 | |||||
EBITDA, 2 Yr. CAGR % | 30.14 | 38.85 | 41.57 | 13.4 | -20.49 | |||||
EBITA, 2 Yr. CAGR % | 32.86 | 38.74 | 42.06 | 12.92 | -22.48 | |||||
EBIT, 2 Yr. CAGR % | 31.54 | 37.26 | 41.62 | 12.16 | -24.33 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 100.09 | 86.48 | 5.81 | -20.38 | -55.6 | |||||
Net Income, 2 Yr. CAGR % | 92.5 | 84.8 | 7.09 | -16.07 | -55.07 | |||||
Normalized Net Income, 2 Yr. CAGR % | 5.34 | 24.47 | 59.82 | 36.13 | -18.26 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 86.45 | 70.89 | 2.93 | -15.79 | -55.02 | |||||
Accounts Receivable, 2 Yr. CAGR % | 29.97 | 34.38 | 51.51 | 31.34 | 13 | |||||
Inventory, 2 Yr. CAGR % | 201.64 | 124.85 | 116.87 | 95.93 | 19.97 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 63.66 | 62.43 | 39.37 | 14.49 | 12.77 | |||||
Total Assets, 2 Yr. CAGR % | 113.49 | 77.53 | 18.62 | 11.81 | 2.21 | |||||
Tangible Book Value, 2 Yr. CAGR % | 200.64 | 132.74 | 7.39 | 5.44 | 1.03 | |||||
Common Equity, 2 Yr. CAGR % | 145.77 | 107.1 | 10.22 | 7.71 | 2.74 | |||||
Cash From Operations, 2 Yr. CAGR % | 38.29 | 64.28 | 16.59 | -10.11 | -10.11 | |||||
Capital Expenditures, 2 Yr. CAGR % | 30.62 | 89.26 | 69.31 | -7.74 | -10.85 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 39.1 | 41.35 | -51.85 | -33.38 | 45.62 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 40.26 | 38.11 | -66.46 | -26.7 | 128.99 | |||||
Dividend Per Share, 2 Yr. CAGR % | 13.4 | 34.11 | 35.4 | 6.58 | -26.15 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 23.69 | 31.35 | 36.22 | 32.25 | 8.19 | |||||
Gross Profit, 3 Yr. CAGR % | 27.86 | 31.8 | 29.18 | 23.4 | -0.39 | |||||
EBITDA, 3 Yr. CAGR % | 31.67 | 37.09 | 36.43 | 25.07 | -5.91 | |||||
EBITA, 3 Yr. CAGR % | 31.96 | 39.22 | 36.46 | 24.92 | -7.42 | |||||
EBIT, 3 Yr. CAGR % | 31.16 | 38.31 | 35.2 | 24.37 | -9.09 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 82.8 | 88.45 | 32.56 | 1.95 | -49.08 | |||||
Net Income, 3 Yr. CAGR % | 79.8 | 82.59 | 33.59 | 4.99 | -47.96 | |||||
Normalized Net Income, 3 Yr. CAGR % | 16.51 | 22.85 | 33.29 | 45.76 | 0.72 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 75.28 | 73.67 | 27.1 | 2.23 | -47.8 | |||||
Accounts Receivable, 3 Yr. CAGR % | 27.86 | 39.05 | 37.58 | 40.03 | 22.58 | |||||
Inventory, 3 Yr. CAGR % | 595.57 | 127.32 | 164.09 | 70.49 | 73.72 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 50.08 | 63.96 | 46.03 | 29.21 | 14.5 | |||||
Total Assets, 3 Yr. CAGR % | 75.91 | 77.02 | 53.88 | 15.02 | 6.49 | |||||
Tangible Book Value, 3 Yr. CAGR % | 116.84 | 115.51 | 78.01 | 7.18 | 2.05 | |||||
Common Equity, 3 Yr. CAGR % | 86.34 | 89.37 | 66.73 | 9.27 | 4.48 | |||||
Cash From Operations, 3 Yr. CAGR % | 46.91 | 39.7 | 37.03 | 4.83 | -8.32 | |||||
Capital Expenditures, 3 Yr. CAGR % | 50.44 | 58.99 | 63.36 | 26.09 | -1.1 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 22.44 | 43.31 | -33.14 | -12.1 | -29.93 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 23.96 | 42.03 | -47.49 | -7.69 | -22.92 | |||||
Dividend Per Share, 3 Yr. CAGR % | 31.05 | 28.93 | 25.54 | 23.71 | -15.66 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 27.24 | 34.73 | 33.24 | 26.27 | 18.69 | |||||
Gross Profit, 5 Yr. CAGR % | 29.1 | 38.43 | 31.13 | 23.47 | 11.49 | |||||
EBITDA, 5 Yr. CAGR % | 31.51 | 48.2 | 35.54 | 27.07 | 9.93 | |||||
EBITA, 5 Yr. CAGR % | 33.32 | 51.76 | 35.91 | 28.03 | 8.84 | |||||
EBIT, 5 Yr. CAGR % | 32.86 | 51.47 | 35.25 | 27.19 | 7.2 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 63.46 | 84.94 | 46.89 | 33.51 | -14.42 | |||||
Net Income, 5 Yr. CAGR % | 62.11 | 82.84 | 46.14 | 33.8 | -13.6 | |||||
Normalized Net Income, 5 Yr. CAGR % | 26.31 | 41.98 | 32.21 | 28 | 9.62 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 55.61 | 75.18 | 41.66 | 30.01 | -16.11 | |||||
Accounts Receivable, 5 Yr. CAGR % | 28.16 | 36.28 | 36.84 | 35.91 | 27.17 | |||||
Inventory, 5 Yr. CAGR % | 60.94 | 152.08 | 336.4 | 114.2 | 92.61 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 28.61 | 41.18 | 45.7 | 42.02 | 31.69 | |||||
Total Assets, 5 Yr. CAGR % | 64.69 | 58.3 | 50.26 | 47.3 | 30.65 | |||||
Tangible Book Value, 5 Yr. CAGR % | 94.72 | 73.92 | 63.71 | 61.91 | 41.92 | |||||
Common Equity, 5 Yr. CAGR % | 74.29 | 61.95 | 51.04 | 51.11 | 37.37 | |||||
Cash From Operations, 5 Yr. CAGR % | 39.99 | 49.3 | 33.94 | 17.11 | 15.77 | |||||
Capital Expenditures, 5 Yr. CAGR % | 12.44 | 42.99 | 57.72 | 27.89 | 28.21 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 47.3 | 98.18 | -16.02 | 5.22 | -7.46 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 48.16 | 90.61 | -26.77 | 8.74 | -2.91 | |||||
Dividend Per Share, 5 Yr. CAGR % | 35.08 | 49.61 | 32.77 | 19.48 | 1.53 |
Select your edition
All financial news and data tailored to specific country editions
















